A UNSW Sydney-led team of scientists has made an advance that could eventually lead to a cure for sickle cell anaemia and other blood disorders.
By introducing a beneficial natural mutation into blood cells using the gene-editing technique CRISPR, a UNSW Sydney-led team of scientists has been able to switch on production of foetal haemoglobin – an advance that could eventually lead to a cure for sickle cell anaemia and other blood disorders.
People with thalassaemia or sickle cell anaemia have damaged adult haemoglobin – the vital molecule that picks up oxygen in the lungs and transports it around the body – and they require life-long treatment with blood transfusions and medication.
However, people with these diseases who also carry the beneficial natural mutation – known as British-198 – have reduced symptoms, because the mutation switches on the foetal haemoglobin gene that is normally turned off after birth.
The extra foetal haemoglobin in their blood, which has a very strong affinity for oxygen, does the work of the defective adult haemoglobin.
“With CRISPR gene-editing we can now precisely cut and alter single genes within our vast genome,” says study senior author and UNSW molecular biologist Professor Merlin Crossley.
“Our laboratory has shown that introducing the beneficial mutation British-198 into blood cells using this technology substantially boosts their production of foetal haemoglobin.
“Because this mutation already exists in nature and is benign, this ‘organic gene therapy’ approach should be effective and safe to use to treat, and possibly cure serious blood disorders. However, more research is still needed before it can be tested in people,” he says.
The study by scientists from UNSW, the Japanese Red Cross Society and the RIKEN BioResource Centre in Japan, is published in the journal Blood.
The beneficial British-198 mutation, which was first identified in a large British family in 1974, involves a change in just a single letter of the genetic code.
Carriers of this mutation have foetal haemoglobins levels as high as 20% of total haemoglobin, while most people’s foetal haemoglobin levels fall to about 1% of total haemoglobin after birth.
The researchers also discovered how this British-198 mutation works. They found it creates a new binding site for a protein called KLF1 that turns blood genes on.
Mutations affecting adult haemoglobin production are among the most common of all genetic variations, with about 5% of the world’s population carrying a defective gene.
“To turn the new gene editing approach into a therapy for blood disorders, the British-198 mutation would have to be introduced into blood-forming stem cells from the patient,” says Professor Crossley.
“A large number of stem cells would have to be edited in order to repopulate the patients’ blood with genetically enhanced cells.”
The Latest on: Genome therapy
[google_news title=”” keyword=”Genome therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophiliaon April 26, 2024 at 11:30 am
FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program.
- FDA Approves One-Time Gene Therapy Fidanacogene Elaparvovec for Hemophilia Bon April 26, 2024 at 6:00 am
The FDA has approved fidanacogene elaparvovec-dzkt (Beqvez; Pfizer), a gene therapy administered in a one-time dose, for certain patients with moderate to severe hemophilia B.
- FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorderon April 26, 2024 at 4:02 am
The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.
- Researchers publish final results of key clinical trial for gene therapy for sickle cell diseaseon April 25, 2024 at 6:14 am
In a landmark study, an international consortium led by researchers at Children's Hospital of Philadelphia (CHOP) published the final results of a key clinical trial of the gene therapy CASGEVY ...
- ASO Therapy Repairs Neurons from Timothy Syndrome Patientson April 24, 2024 at 5:00 pm
These experiments show a new genetic rescue strategy for a devastating neurodevelopmental ... Pașca, MD, lab to test the ASO therapy’s effectiveness in vivo. In this setup, human stem cell-derived ...
- Gene-based therapy restores cellular development and function in brain cells from people with Timothy syndromeon April 24, 2024 at 10:18 am
In a proof-of-concept study, researchers demonstrated the effectiveness of a potential new therapy for Timothy syndrome, an often life-threatening and rare genetic disorder that affects a wide range ...
- Another delay for Abeona's topical gene therapy pz-cel as FDA sends out a rejectionon April 23, 2024 at 8:16 am
Abeona had hoped that a meeting with FDA on March 21 and commitments to provide CMC data before the PDUFA date and post-approval validation reports would keep pz-cel on track. But the FDA said in the ...
- Documentary about a family’s journey to Minnesota for gene therapy premieres in Minneapolison April 22, 2024 at 12:47 pm
Celia Grace Hamlett was 4 years old when she became the first person in the U.S. to undergo an experimental gene therapy for a rare disease.
- A small factor makes a big impact on genome editingon April 22, 2024 at 8:52 am
Through years of engineering gene-editing systems, researchers have developed a suite of tools that enable the modification of genomes in living cells, akin to "genome surgery." These tools, including ...
- The future of gene therapy has arrived, and it's changing lives for the betteron April 21, 2024 at 5:12 pm
Ohio State University's Wexner Medical Center research is exploring the field of gene therapy to help people with rare genetic disorders.
via Google News and Bing News